« Back to Record
Gelber, R., Wang, X. V., Cole, B. B., Cameron, D. A., Cardoso, F., Tjan-Heijnen, V. C. G., Krop, I., Loi, S., Salgado, R., Kiermaier, A., Frank, E. E., Fumagalli, D., Caballero, C., de Azambuja, E., Procter, M., Clark, E., Restuccia, E., Heeson, S., Bines, J., Loibl, S., & Piccart-Gebhart, M. (2022). Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial. European journal of cancer, 166, 219-228. doi:10.1016/j.ejca.2022.01.031
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/341629



